Yıl: 2019 Cilt: 41 Sayı: 3 Sayfa Aralığı: 312 - 315 Metin Dili: İngilizce DOI: 10.14744/etd.2019.43179 İndeks Tarihi: 29-01-2020

Economic Burden of Multidrug-Resistant Gram-Negative Infections in a Developing Country

Öz:
Objective: Antibiotic-resistant infections represent a significant global public health threat due to their rising prevalence.The aim of this study is to identify risk factors for acquisition of multidrug-resistant gram negatives (MDR-GNs) in the firstintensive care unit (ICU) infection episode of patients and also to calculate the economic burden of infection with MDR-GNsthat the ICU patient faced.Materials and Methods: This is a prospective observational study conducted over 1 year. The first ICU infection episode ofthe patients was included into this study. A case was defined as a patient who had an MDR-GN in his or her first episode ofan ICU infection, and control was defined as a patient who had a non-MDR-GN in his or her first episode of an ICU infection.Results: A total of 100 patients were included into the study. Sixty-two patients had the MDR-GN, and 38 patients had anon-MDR pathogen. Independent risk factors associated with the MDR-GN infection were the APACHE II score (OR=1.08,p=0.012), transfer from another hospital (OR=9.3, p=0.04), antibiotic use before ICU infection (OR=7.7, p=0.04), and arterial catheter (OR=2.8, p=0.03). The median antibiotic cost was significantly higher for patients in the case group [$663.50(27–3,752) and $256.00 (0–2,716), respectively] (p<0.01). Also, a total hospital cost for patients was significantly higher inthe case group ($8,895 [2,621–23,883] and $6,551 [1,441–20,425], respectively) (p<0.05).Conclusion: Patients with a high APACHE II score transferred from another hospital and who use an antibiotic before theICU infection and arterial catheter are at a greater risk of MDR-GN infections. Also, the infections pose a significant burdenon health care facilities due to more prolonged and costly treatments.
Anahtar Kelime:

Konular: Genel ve Dahili Tıp
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • Giske CG, Monnet DL, Cars O, Carmeli Y; ReAct-Action on Antibiotic Resistance. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 2008; 52(3): 813–21. [CrossRef]
  • Cerceo E, Deitelzweig SB, Sherman BM, Amin AN. Multidrug-Resistant Gram-Negative Bacterial Infections in the Hospital Setting: Overview, Implications for Clinical Practice, and Emerging Treatment Options. Microb Drug Resist 2016; 22(5): 412–31. [CrossRef]
  • Siwakoti S, Subedi A, Sharma A, Baral R, Bhattarai NR, Khanal B. Incidence and outcomes of multidrug-resistant gram-negative bacteria infections in intensive care unit from Nepal- a prospective cohort study. Antimicrob Resist Infect Control 2018; 7: 114. [CrossRef]
  • Centers for Disease Control and Prevention/ National Healthcare Safety Network. CDC/ NHSN Surveillance Definitions for Specific Types of Infections. January 2017. Available from: URL: https:// www.cdc.gov/ nhsn/ pdfs/ pscmanual/ 17pscnos infdef_current.pdf.
  • Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18(3): 268–81. [CrossRef]
  • Oliva A, Giacobbe DR, Di Luca M, Miller NS. New Insights into Infections due to Multidrug Resistant Gram Negative Bacteria: The Interplay between Lab and Clinic. Biomed Res Int 2018; 2018: 8905874.
  • Ibrahim ME. High antimicrobial resistant rates among Gram-negative pathogens in intensive care units. A retrospective study at a tertiary care hospital in Southwest Saudi Arabia. Saudi Med J 2018; 39(10): 1035–43. [CrossRef]
  • Thaden JT, Li Y, Ruffin F, Maskarinec SA, Hill-Rorie JM, Wanda LC, et al. Increased Costs Associated with Bloodstream Infections Caused by Multidrug-Resistant Gram-Negative Bacteria Are Due Primarily to Patients with Hospital-Acquired Infections. Antimicrob Agents Chemother 2017; 61(3).pii: e01709–16. [CrossRef]
  • Ulu-Kilic A, Alp E, Percin D, Cevahir F, Altay-Kürkçü C, Ozturk A, et al. Risk factors for carbapenem resistant Klebsiella pneumoniae rectal colonization in pediatric units. J Infect Dev Ctries 2014; 8(10): 1361–4.
  • Halaby T, Al Naiemi N, Beishuizen B, Verkooijen R, Ferreira JA, Klont R, et al. Impact of single room design on the spread of multi-drug resistant bacteria in an intensive care unit. Antimicrob Resist Infect Control 2017; 6: 117. [CrossRef]
APA ULU KILIÇ A, KALIN ÜNÜVAR G, CEVAHİR F, Alp E (2019). Economic Burden of Multidrug-Resistant Gram-Negative Infections in a Developing Country. , 312 - 315. 10.14744/etd.2019.43179
Chicago ULU KILIÇ Ayşegül,KALIN ÜNÜVAR Gamze,CEVAHİR Fatma,Alp Emine Economic Burden of Multidrug-Resistant Gram-Negative Infections in a Developing Country. (2019): 312 - 315. 10.14744/etd.2019.43179
MLA ULU KILIÇ Ayşegül,KALIN ÜNÜVAR Gamze,CEVAHİR Fatma,Alp Emine Economic Burden of Multidrug-Resistant Gram-Negative Infections in a Developing Country. , 2019, ss.312 - 315. 10.14744/etd.2019.43179
AMA ULU KILIÇ A,KALIN ÜNÜVAR G,CEVAHİR F,Alp E Economic Burden of Multidrug-Resistant Gram-Negative Infections in a Developing Country. . 2019; 312 - 315. 10.14744/etd.2019.43179
Vancouver ULU KILIÇ A,KALIN ÜNÜVAR G,CEVAHİR F,Alp E Economic Burden of Multidrug-Resistant Gram-Negative Infections in a Developing Country. . 2019; 312 - 315. 10.14744/etd.2019.43179
IEEE ULU KILIÇ A,KALIN ÜNÜVAR G,CEVAHİR F,Alp E "Economic Burden of Multidrug-Resistant Gram-Negative Infections in a Developing Country." , ss.312 - 315, 2019. 10.14744/etd.2019.43179
ISNAD ULU KILIÇ, Ayşegül vd. "Economic Burden of Multidrug-Resistant Gram-Negative Infections in a Developing Country". (2019), 312-315. https://doi.org/10.14744/etd.2019.43179
APA ULU KILIÇ A, KALIN ÜNÜVAR G, CEVAHİR F, Alp E (2019). Economic Burden of Multidrug-Resistant Gram-Negative Infections in a Developing Country. Erciyes Medical Journal, 41(3), 312 - 315. 10.14744/etd.2019.43179
Chicago ULU KILIÇ Ayşegül,KALIN ÜNÜVAR Gamze,CEVAHİR Fatma,Alp Emine Economic Burden of Multidrug-Resistant Gram-Negative Infections in a Developing Country. Erciyes Medical Journal 41, no.3 (2019): 312 - 315. 10.14744/etd.2019.43179
MLA ULU KILIÇ Ayşegül,KALIN ÜNÜVAR Gamze,CEVAHİR Fatma,Alp Emine Economic Burden of Multidrug-Resistant Gram-Negative Infections in a Developing Country. Erciyes Medical Journal, vol.41, no.3, 2019, ss.312 - 315. 10.14744/etd.2019.43179
AMA ULU KILIÇ A,KALIN ÜNÜVAR G,CEVAHİR F,Alp E Economic Burden of Multidrug-Resistant Gram-Negative Infections in a Developing Country. Erciyes Medical Journal. 2019; 41(3): 312 - 315. 10.14744/etd.2019.43179
Vancouver ULU KILIÇ A,KALIN ÜNÜVAR G,CEVAHİR F,Alp E Economic Burden of Multidrug-Resistant Gram-Negative Infections in a Developing Country. Erciyes Medical Journal. 2019; 41(3): 312 - 315. 10.14744/etd.2019.43179
IEEE ULU KILIÇ A,KALIN ÜNÜVAR G,CEVAHİR F,Alp E "Economic Burden of Multidrug-Resistant Gram-Negative Infections in a Developing Country." Erciyes Medical Journal, 41, ss.312 - 315, 2019. 10.14744/etd.2019.43179
ISNAD ULU KILIÇ, Ayşegül vd. "Economic Burden of Multidrug-Resistant Gram-Negative Infections in a Developing Country". Erciyes Medical Journal 41/3 (2019), 312-315. https://doi.org/10.14744/etd.2019.43179